Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

13.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.4K
Histone Modification02:32

Histone Modification

13.0K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SHIELD: A weakly supervised graph attention neural network for decoding disease-relevant cell-cell interactions.

Patterns (New York, N.Y.)·2026
Same author

Screen for Tissue-Specific Markers of Drug-Induced Phospholipidosis Using Mass Spectrometry Imaging.

Journal of the American Society for Mass Spectrometry·2026
Same author

Pharmacological activation of NO-cGMP signalling attenuates metabolic dysfunction-associated steatohepatitis.

British journal of pharmacology·2026
Same author

Endometriosis-related alterations in the endometrium revealed by integrated single-cell and AI-powered approaches.

Nature communications·2026
Same author

Noninvasive in vivo imaging of NF-κB activation predicts immunotherapy response in solid tumors.

Npj imaging·2026
Same author

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.

ImmunoTargets and therapy·2026

Related Experiment Video

Updated: May 29, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase

Louise Kaldjob-Heinrich1, Sandro Nuciforo2,3, Steffen Lemke4,5

  • 1Department Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.

Gastro Hep Advances
|February 6, 2025
PubMed
Summary

Novel liver cancer treatments targeting Adenosine A3 receptor (ADORA3) show promise. Namodenoson, an ADORA3 agonist, combined with epigenetic drugs, demonstrated significant anti-cancer effects in hepatocellular carcinoma and cholangiocarcinoma models.

Keywords:
Adenosine Receptor 3Cancer Combination TherapyCholangiocarcinomaEpigeneticHepatocellular Carcinoma

More Related Videos

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.4K
Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue
08:12

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Published on: May 5, 2022

3.8K

Related Experiment Videos

Last Updated: May 29, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K
Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.4K
Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue
08:12

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Published on: May 5, 2022

3.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Primary liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), has limited treatment options.
  • Adenosine A3 receptor (ADORA3) signaling is a potential therapeutic target.
  • Namodenoson, an ADORA3 agonist, has shown early promise in HCC clinical trials.

Purpose of the Study:

  • To investigate ADORA3 expression patterns in liver cancer.
  • To elucidate the mechanisms of action of ADORA3 agonists.
  • To evaluate combination therapies involving ADORA3 agonists for HCC and CCA.

Main Methods:

  • Patient-derived tissue microarrays and RNA-sequencing were used to assess ADORA3 expression.
  • Cellular responses to ADORA3 stimulation and combination treatments were studied in HCC/CCA cell lines and patient-derived organoids (PDOs).
  • Genome-wide RNA-Seq, mRNA analysis, and DigiWest protein profiling were performed.

Main Results:

  • ADORA3 expression varied significantly in HCC and CCA tumors, with higher expression in nonmalignant tissues.
  • The ADORA3 agonist Namodenoson exhibited antiproliferative effects in cancer cell lines and PDOs, dependent on ADORA3.
  • Combination treatments with ADORA3 agonists and histone deacetylase inhibitors enhanced antiproliferative effects, suggesting epigenetic modulation.

Conclusions:

  • ADORA3 expression levels can potentially stratify patients for clinical studies in HCC and CCA.
  • Namodenoson's epigenetic effects indicate that epigenetic drugs are promising partners for combination therapy.
  • Targeting ADORA3 signaling offers a novel therapeutic strategy for liver cancer, particularly in combination regimens.